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1. INTRODUCTION {#cam41904-sec-0005}
===============

Radiotherapy is the recommended treatment after breast‐conserving surgery (BCS) for early‐stage breast cancer (BC). However, it is not clear whether the addition of radiotherapy after BCS results in improved survival in elderly women diagnosed with early‐stage hormone receptor‐positive (HR+) BC. The use of radiotherapy in elderly women has decreased following the Cancer and Leukemia Group B (CALGB) C9343 trial\'s conclusion that adjuvant radiotherapy did not improve survival in elderly patients with HR+ BC.[1](#cam41904-bib-0001){ref-type="ref"} Subsequent studies have reported similar findings.[2](#cam41904-bib-0002){ref-type="ref"}, [3](#cam41904-bib-0003){ref-type="ref"} Based on these trial results, the National Comprehensive Cancer Network (NCCN) guidelines recommend that adjuvant radiotherapy be omitted for patients 70 years and older with T1N0M0 ER+HER2‐negative BC.[9](#cam41904-bib-0009){ref-type="ref"} Conversely, findings from observational studies showed that the addition of radiotherapy after BCS was associated with improved survival of elderly women.[10](#cam41904-bib-0010){ref-type="ref"}, [11](#cam41904-bib-0011){ref-type="ref"} These studies proposed that radiotherapy be considered a noteworthy aspect of a treatment plan for appropriately selected elderly patients and that age should not be the only factor to consider when making decisions about whether elderly patients with early‐stage BC should receive radiotherapy.[10](#cam41904-bib-0010){ref-type="ref"}, [11](#cam41904-bib-0011){ref-type="ref"}

Some of the differences between the results of randomized clinical trials (RCTs) and observational studies may derive from the limitations of these studies' designs. On the one hand, RCTs are often shorter in duration and conducted in controlled environments with highly selected patients; they may not be generalizable to everyday clinical practice characterized by more heterogeneity in patient population, providers, and health care delivery systems.[12](#cam41904-bib-0012){ref-type="ref"}, [13](#cam41904-bib-0013){ref-type="ref"} On the other hand, the most important limitation of the nonrandomization of observational studies is selection bias,[14](#cam41904-bib-0014){ref-type="ref"} which occurs when the treatment and control groups are systematically different from one another. These factors can be associated with the outcome and the choice of treatment.[15](#cam41904-bib-0015){ref-type="ref"}, [16](#cam41904-bib-0016){ref-type="ref"}

There is accordingly a critical need to generate robust evidence regarding survival benefits associated with radiotherapy after BCS in elderly patients with early‐stage HR+ BC. This evidence can be used to optimize the use of radiotherapy to avoid under or overtreatment and improve clinical decision‐making for elderly patients with early‐stage HR+ BC.

The aim of this study was to estimate the survival benefit associated with radiotherapy plus hormonal therapy (HT) vs HT alone for early‐stage HR+ BC to inform clinical decision‐making.

2. METHODS {#cam41904-sec-0006}
==========

2.1. Study population and data sources {#cam41904-sec-0007}
--------------------------------------

We studied women diagnosed with early‐stage (stage I--IIB) HR+ BC who had undergone surgical treatment identified in Surveillance, Epidemiology, and End Results (SEER)‐Medicare data. The 6th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual was used to identify early‐stage BC. We identified patients who received surgical treatment, radiotherapy, HT, and a combination of radiotherapy and HT. We included data from 2006 to 2011 pertaining to women aged 65 and older at diagnosis who were enrolled in Medicare Part A and Part B. Patients who enrolled in Health Maintenance Organizations (HMOs) and patients diagnosed through autopsy or by death certificate were excluded.

2.2. Treatment, outcome, and covariates {#cam41904-sec-0008}
---------------------------------------

We compared radiotherapy plus HT vs HT alone after BCS. Adjuvant systemic treatments were identified as the receipt of radiotherapy using Healthcare Common Procedure Coding system codes (HCPCS), International Classification of Diseases, Ninth Revision Clinical Modification (ICD‐9‐CM) codes, brand name (bn) or generic name (gn) or "Tamoxifen Citrate" for Tamoxifen to identify HT status. See Table [S1](#cam41904-sup-0003){ref-type="supplementary-material"} for detailed treatment identification. Overall survival (OS) times were calculated as "number of years" from the date of diagnosis to the date of death or termination of the study. Death from all causes was the event of interest.

Patient demographics and clinical and area‐level characteristics were obtained from the Patient Entitlement and Diagnosis Summary File (PEDSF). Charlson comorbidity scores were derived from Medicare Provider Analysis and Review (MEDPAR), National Claims History (NCH), and outpatient files during the 12 months preceding the diagnosis utilizing ICD‐9 codes. Hospital characteristics were identified from the hospital file.

2.3. Statistical analysis {#cam41904-sec-0009}
-------------------------

The baseline characteristics of patients receiving radiotherapy plus HT and HT alone were compared using the Student\'s *t* test for continuous variables and the chi‐squared test for categorical variables assuming equal variance. Because the treatment assignments were not random, propensity score (PS) matching analysis was performed. The use of PS matching ensures equivalence in the distribution of observed confounders between the two treatment groups. A two‐stage PS matching approach was adopted. In the first stage, we estimated the probability of receiving treatment (PS) given the observed covariates using a logistic model (see Table [S2](#cam41904-sup-0003){ref-type="supplementary-material"}). We matched the control group (HT alone) with the treatment group (radiotherapy plus HT) after BCS using a one‐to‐one greedy matching procedure with a caliper equal to one‐fifth of the standard deviation (SD).[17](#cam41904-bib-0017){ref-type="ref"} The second stage consisted of estimating the survival benefit.

The balance in baseline covariates between the HT alone and radiotherapy plus HT groups was assessed using graphical and analytical approaches. We plotted and compared the distribution of PS for the HT alone and radiotherapy plus HT groups before and after matching. The overall quality of matching was assessed by calculating the absolute standardized differences (ASDs) for each baseline covariate. We compared the pseudo *R* ^2^ for unmatched and matched data from the logistic regression.

After PS matching, survival was assessed using Kaplan‐Meier survival curves; group differences were compared using the log‐rank test. Cox proportional hazard (PH) models were fit to determine any association between radiotherapy plus HT and patient survival. Hazard ratios, *P*‐values, and 95% confidence intervals were calculated. The event of interest in this study was all‐cause death. The observation times were censored at the study calendar time (December 31, 2014) for patients who were alive at the end of the study. Before applying the Cox PH models, we tested the proportionality assumption by visual inspection and analytical tests. We used the Stata*stphplot* graphical test to plot the log‐log transformation of the survival function.[18](#cam41904-bib-0018){ref-type="ref"}, [19](#cam41904-bib-0019){ref-type="ref"} The scaled Schoenfeld residuals test for PH assumption was used as an analytical test.[20](#cam41904-bib-0020){ref-type="ref"} We used time‐dependent variables for the parameters that violated the PH assumption. All of the data were deidentified such that individual patient health information was untracked. An institutional review board exemption was obtained before the initiation of the study. All of the analyses were performed using the SAS version 9.4 and STATA version 14.0 statistical software packages (SAS Institute Inc., Cary, NC, USA).

3. RESULTS {#cam41904-sec-0010}
==========

3.1. Patient characteristics before PS matching {#cam41904-sec-0011}
-----------------------------------------------

A total of 5688 patients satisfied the inclusion criteria (Figure [1](#cam41904-fig-0001){ref-type="fig"}). Within this total group, 1549 patients (27.23%) were treated with HT and 4139 patients (72.77%) were treated with radiotherapy plus HT after BCS.

![Summary of data extraction. BC, breast cancer; BCS, breast‐conserving surgery; HR+, hormone receptor positive; HR−, hormone receptor negative; N = number of records](CAM4-8-117-g001){#cam41904-fig-0001}

Patient characteristics, facility characteristics, and area‐level information by treatment type are listed in Table [1](#cam41904-tbl-0001){ref-type="table"}. The average age at diagnosis was 72.7 years (SD = 5.89 years). Patients who were treated with HT alone after BCS were relatively older than patients who were treated with radiotherapy plus HT (74.81 years vs 72.05 years; *P* \< 0.0001). Most of the patients were white (87.05%), and there were several important differences between the HT and the radiotherapy plus HT groups. A large proportion of patients who received HT alone after BCS were single; married women tended to receive radiotherapy plus HT. Patients who were treated with radiotherapy plus HT tended to be diagnosed with a moderately differentiated tumor grade (49.38%), a tumor between 0 and 2 cm in size (81.31%), and no positive lymph node involvement (79.06%). The majority of the women in the radiotherapy plus HT and HT‐only groups had no comorbidities. Among women treated with radiotherapy, 79.06% had no major comorbidities. Among those with known HER2 status, a larger proportion of patients who received radiotherapy plus HT were diagnosed with HER2‐negative BC. Patients who received HT alone had a greater proportion of node‐positive BC compared with patients who received RT (*P* \< 0.0001).

###### 

Descriptive characteristics of the study patients by treatment group

  Characteristics                              Women with breast cancer (N = 5688)   Breast cancer cases by treatment type                  
  -------------------------------------------- ------------------------------------- --------------------------------------- -------------- ---------
  Death                                                                                                                                     
  Breast                                       47 (0.83)                             28 (1.81)                               19 (0.46)      \<.0001
  All cause                                    303 (5.33)                            185 (11.94)                             118 (2.85)     \<.0001
  Age in years, N (%)                                                                                                                       
  Mean age at diagnosis, mean (SD)             72.80 (5.89)                          74.81 (6.78)                            72.05 (5.18)   \<.0001
  Between 65 and 69                            2016 (35.44)                          416 (26.86)                             1600 (38.66)   
  Between 70 and 74                            1650 (29.01)                          401 (25.89)                             1249 (30.18)   
  Between 75 and 79                            1243 (21.85)                          341 (22.01)                             902 (21.79)    
  80 and above                                 779 (13.70)                           391 (25.24)                             388 (9.37)     
  Race, N (%)                                                                                                                               
  White                                        4946 (87.05)                          1304 (84.29)                            3642 (88.08)   0.0024
  Black                                        353 (6.21)                            117 (7.56)                              236 (5.71)     
  Others                                       383 (6.74)                            126 (8.14)                              257 (6.22)     
  Marital status, N (%)                                                                                                                     
  Married                                      2892 (50.84)                          661 (42.67)                             2231 (53.90)   \<.0001
  Unmarried                                    2532 (44.51)                          806 (52.03)                             1726 (41.70)   
  Unknown                                      264 (4.64)                            82 (5.29)                               182 (4.40)     
  Charlson comorbidity                                                                                                                      
  0                                            3546 (62.34)                          835 (53.91)                             2711 (65.5)    \<.0001
  1‐3                                          2007 (35.28)                          658 (42.48)                             1349 (32.59)   
  ≥4                                           135 (2.37)                            56 (3.62)                               79 (1.91)      
  Grade, N (%)                                                                                                                              
  Well differentiated                          1772 (31.15)                          483 (31.18)                             1289 (31.14)   0.1494
  Moderately differentiated                    2771 (48.72)                          727 (46.93)                             2044 (49.38)   
  Poorly differentiated and undifferentiated   879\. (15.45)                         255 (16.46)                             624 (15.08)    
  Unknown/inapplicable                         266 (4.68)                            84 (5.42)                               182 (4.40)     
  Tumor size, N (%)                                                                                                                         
  0‐2 cm                                       4509 (79.27)                          1151 (74.31)                            3358 (81.31)   \<.0001
  2‐5 cm                                       1020 (17.93)                          351 (22.66)                             669 (16.16)    
  ≥5 cm                                        159 (2.80)                            47 (3.03)                               112 (2.71)     
  Number of positive lymph nodes, N (%)                                                                                                     
  0                                            4357 (76.65)                          1087 (70.22)                            3270 (79.06)   \<.0001
  1‐3                                          875 (15.39)                           260 (16.80)                             615 (14.87)    
  ≥4                                           452 (7.95)                            201 (12.98)                             251 (6.07)     
  HER2, N (%)                                                                                                                               
  Positive                                     113 (1.99)                            35 (2.26)                               78 (1.88)      0.5732
  Negative                                     1418 (24.93)                          393 (25.35)                             1025 (24.76)   
  Unknown                                      4157 (73.08)                          1121 (72.37)                            3036 (73.35)   
  Year of diagnosis, N (%)                                                                                                                  
  2006                                         1647 (28.96)                          397 (25.63)                             1250 (30.20)   0.0241
  2007                                         815 (14.33)                           243 (15.69)                             572 (13.82)    
  2008                                         839 (14.75)                           237 (15.30)                             602 (14.54)    
  2009                                         768 (13.50)                           217 (14.01)                             551 (13.31)    
  2010                                         819 (14.40)                           237 (15.30)                             582 (14.06)    
  2011                                         800 (14.06)                           218 (14.07)                             582 (14.06)    
  Metropolitan area, N (%)                                                                                                                  
  Yes                                          5030 (88.43)                          1272 (82.12)                            3758 (90.97)   \<.0001
  No                                           658 (11.57)                           277 (17.88)                             381 (9.21)     
  Geographic regions, N (%)                                                                                                                 
  North East                                   1348 (23.70)                          293 (18.92)                             1055 (25.49)   \<.0001
  Midwest                                      752 (13.22)                           192 (12.40)                             560 (13.53)    
  South                                        1322 (23.24)                          496 (32.02)                             826 (19.96)    
  West                                         2266 (39.84)                          568 (36.67)                             1698 (41.02)   
  Poverty level (%)                                                                                                                         
  0‐5                                          1703 (29.99)                          342 (22.12)                             1361 (32.93)   \<.0001
  5‐10                                         1568 (27.61)                          389 (25.16)                             1179 (28.53)   
  10‐20                                        1511 (26.60)                          473 (30.60)                             1038 (24.12)   
  20‐100                                       897 (15.80)                           372 (22.12)                             555 (13.43)    
  Referral hospital, N (%)                                                                                                                  
  Yes                                          254 (4.47)                            98 (6.33)                               156 (3.77)     \<.0001
  No                                           3120 (54.85)                          1009 (65.14)                            2111 (51.00)   
  Unknown                                      2314 (40.68)                          442 (28.53)                             1872 (45.23)   
  Survival time year                                                                                                                        
  Mean                                                                                                                                      
  Overall survival                             5.22 (1.86)                           4.92 (1.84)                             5.32 (1.86)    \<.0001

HER2, human epidermal growth factor receptor; N, number of records; (%), column percentage.

John Wiley & Sons, Ltd

During the study period, 303 deaths occurred. There were 185 (11.94%) deaths among patients treated with HT alone, and 118 (2.85%) deaths among patients treated with radiotherapy plus HT (*P* \< 0.0001). The mean OS time was 5.22 years (SD = 0.01 years). Compared with patients treated with HT alone, patients treated with radiotherapy plus HT had a relatively longer average survival time (4.92 years vs 5.32 years; *P* \< 0.0001).

3.2. PS matching {#cam41904-sec-0012}
----------------

Nine hundred and thirty‐six of the 4218 radiation‐treated patients were matched with 936 of the 1591 HT patients. The numbers of deaths from any causes in the HT and radiotherapy plus HT groups were 106 and 67, respectively. The mean survival time after PS matching for the radiotherapy plus HT group was 5.18 ± 1.80 years; the mean survival time in the HT group was 5.10 ± 1.80X years.

The balancing property of PS matching was satisfied with six optimal final numbers of blocks. Table [S2](#cam41904-sup-0003){ref-type="supplementary-material"} lists the distribution of patient baseline characteristics before and after PS matching. There were no statistically significant differences in baseline patient characteristics after PS matching.

Figure [2](#cam41904-fig-0002){ref-type="fig"} shows a nonparametric density estimate of the distribution of the estimated PS before and after matching for each patient group. The estimated ASDs are \<0.1 (see Table [S3](#cam41904-sup-0003){ref-type="supplementary-material"}), and the *R* ^2^ was reduced to 0.0053 from 0.0746 after matching. Consequently, the balancing assumption was successfully satisfied.

![Propensity score density graph for the treatment groups. A, Propensity score density graph for treatment groups before matching; B, Propensity score density graph for treatment groups after matching. Hormonal Rx + Radio Rx = HT plus radiotherapy (blue line); Hormonal Rx = HT alone (red line)](CAM4-8-117-g002){#cam41904-fig-0002}

3.3. Survival analysis {#cam41904-sec-0013}
----------------------

Figure [3](#cam41904-fig-0003){ref-type="fig"} shows the Kaplan‐Meier curve and compares the OS for the radiotherapy plus HT and HT alone after BCS groups. The unadjusted analysis indicates that patients who underwent radiotherapy plus HT had a higher OS rate compared with patients treated with HT alone after BCS (*P* \< 0.0001).

![Kaplan‐Meier estimates of OS. A, Kaplan‐Meier estimates of OS for all patients (before PS matching); B, Kaplan‐Meier estimates of OS for matched patients with HT vs radiotherapy plus HT. Hormonal Rx + Radio Rx = HT plus radiotherapy (red line); Hormonal Rx = HT alone (dashed blue line). The *y* axis is the probability of survival, and the *x* axis is time to survival in years](CAM4-8-117-g003){#cam41904-fig-0003}

Prior to the PS matching, the graphical test revealed survival curves that were not parallel, suggesting that the PH assumption condition was likely to be violated (Figure [S1](#cam41904-sup-0001){ref-type="supplementary-material"}A). The analytical test (scaled Schoenfeld residuals test) for the PH assumption indicated that age at diagnosis (*P*‐value \< 0.000) and year of diagnosis (*P*‐value = 0.044) violated the proportionality assumption. Therefore, we used time‐dependent variables for the parameters that violated the PH assumption. After PS matching, the graphical (Figure [S1](#cam41904-sup-0001){ref-type="supplementary-material"}B) and analytical tests confirmed that the PH assumption was satisfied.

Cox PH models were fit to the unmatched and matched datasets. The results of the multivariate Cox PH model for the unmatched data are presented in Table [2](#cam41904-tbl-0002){ref-type="table"}. These results suggest that patients who received radiotherapy plus HT after BCS had their risk of death significantly decreased by 32% (hazard ratio \[HR\] = 0.68; *P*‐value = 0.012) compared with patients who received HT alone. There was no statistically significant difference in OS as a function of race.

###### 

Multivariate Cox proportional hazards regression predictors of overall survival (N = 3050)

                                                                      Hazard. ratio   95% confidence interval   *P*‐value   
  ------------------------------------------------------------------- --------------- ------------------------- ----------- -------
  Treatment                                                                                                                 
  RadioRx + Hormonal Rx vs Hormonal Rx                                0.683           0.508                     0.918       0.012
  Age at diagnosis                                                                                                          
  Age 70 and 74 vs Age 65 and 69                                      0.241           0.049                     1.202       0.083
  Age75 and 79 vs Age 65 and 69                                       0.078           0.009                     0.662       0.019
  Age 80+ vs Age 65 and 69                                            13.495          4.507                     40.408      0
  Race                                                                                                                      
  Black vs White                                                      1.540           0.882                     2.689       0.129
  Other vs White                                                      0.758           0.379                     1.514       0.433
  Marital status                                                                                                            
  Married vs not married                                              0.945           0.682                     1.309       0.733
  Charlson comorbidity                                                                                                      
  1‐3 vs 0                                                            1.604           1.191                     2.159       0.002
  ≥4 vs 0                                                             1.841           0.978                     3.465       0.059
  Tumor Grade                                                                                                               
  Moderately differentiated vs Well differentiated                    1.119           0.784                     1.598       0.536
  Poorly differentiated and undifferentiated vs Well differentiated   1.043           0.669                     1.626       0.853
  Tumor size (cm)                                                                                                           
  2‐4 vs \<2                                                          1.606           1.174                     2.197       0.003
  ≥ 5 vs \<2                                                          1.853           0.846                     4.058       0.123
  Number of node‐positive                                                                                                   
  1‐3 vs 0                                                            1.435           0.958                     2.148       0.08
  ≥ 4 vs 0                                                            1.778           1.282                     2.466       0.001
  Metropolitan area                                                                                                         
  Yes vs No                                                           0.843           0.5184313                 1.37004     0.49
  Referral hospital                                                                                                         
  Yes vs No                                                           0.895           0.547                     1.463       0.658
  Year of diagnosis                                                                                                         
  2007 vs 2006                                                        1.203           0.756                     1.913       0.437
  2008 vs 2006                                                        0.763           0.358                     1.625       0.483
  2009 vs 2006                                                        0.817           0.324                     2.059       0.668
  2010 vs 2006                                                        0.377           0.113                     1.260       0.113
  2011 vs 2006                                                        0.136           0.017                     1.063       0.057
  Geographic regions                                                                                                        
  Midwest vs Northeast                                                1.295           0.795                     2.109       0.298
  West vs Northeast                                                   1.181           0.762                     1.828       0.457
  South vs Northeast                                                  1.226           0.833                     1.805       0.301
  Poverty level                                                                                                             
  5%‐10% vs 0%‐5%                                                     1.069           0.722                     1.583       0.737
  10%‐20% vs 0%‐5%                                                    1.034           0.696                     1.535       0.87
  20%‐100% vs 0%‐5%                                                   1.352           0.871                     2.100       0.179
  Interaction with ln(time)                                                                                                 
  Age                                                                 1.774           1.259                     2.500       0.001
  Year of diagnosis                                                   0.771           0.598                     0.993       0.044

John Wiley & Sons, Ltd

The stratum age 80+ was associated with an elevated risk of dying immediately after diagnosis (HR = 13.5, *P* = 0.00) compared with the group of patients diagnosed between the ages of 65 and 69. The interaction between the natural log of time and age at diagnosis suggests that the hazard intensifies with the increasing age of diagnosis. Women with multiple comorbidities had a higher risk of death compared with women with no comorbidities.

Patients who had one or more positive lymph nodes had a higher risk of death compared with women who had no positive lymph nodes. Compared with patients diagnosed with a tumor size \<2 cm, patients diagnosed with a tumor size of 2‐4 cm had a shorter survival time. The interaction between year of diagnosis and the natural log of time suggests that the hazard decreases diagnoses made more recently.

In the PS‐matched sample, patients who were treated with radiotherapy plus HT exhibited a 38% lower risk of death compared with patients who had received only HT. Based on the three analyses we conducted, we found a higher risk of death among women who were treated only with HT after undergoing BCS compared with women who were treated with the combination therapy (Table [3](#cam41904-tbl-0003){ref-type="table"}).

###### 

All‐cause mortality and radiotherapy plus hormonal therapy use compared to hormonal therapy only

  Model                                             Hazard ratio   95% CI        *P*‐value
  ------------------------------------------------- -------------- ------------- -----------
  Crude                                             0.217          0.172‐0.273   0.000
  Adjusted[a](#cam41904-note-0003){ref-type="fn"}   0.683          0.508‐0.918   0.012
  Propensity score‐matched cohort                   0.621          0.458‐0.844   0.002

Adjusted for age, race, gender, marital status, comorbidities, tumor grade and size, number of node‐positive, year of diagnosis, socioeconomic status, area of residence, and types of hospital (referral vs nonreferral hospital).

John Wiley & Sons, Ltd

Cox‐Snell residual analysis revealed that the hazard function superimposed relatively well with the 45‐degree line except at very large time values (Figure [S2](#cam41904-sup-0002){ref-type="supplementary-material"}), which is common for censored data. As a result, the Cox model was a good fit to the data.

4. DISCUSSION {#cam41904-sec-0014}
=============

This study aimed to compare real‐world survival rates among patients treated with radiotherapy plus HT vs patients treated with HT only in a cohort of elderly early‐stage HR+ BC patients. Our results showed that radiotherapy plus HT significantly improves the OS of elderly women diagnosed with HR+ BC after PS matching. We controlled for individual, area, and facility‐level information. These findings could inform BC treatment decisions made by the elderly.

The findings of RCTs[1](#cam41904-bib-0001){ref-type="ref"}, [2](#cam41904-bib-0002){ref-type="ref"}, [3](#cam41904-bib-0003){ref-type="ref"}, [4](#cam41904-bib-0004){ref-type="ref"} have demonstrated the absence of a survival benefit from the addition of radiotherapy after BCS for elderly patients diagnosed with less‐aggressive, early‐stage BC. As a result, the NCCN guidelines support the possible omission of radiotherapy after BCS. In contrast to the findings of RCTs,[2](#cam41904-bib-0002){ref-type="ref"}, [3](#cam41904-bib-0003){ref-type="ref"} our study shows that the addition of radiotherapy was associated with improved OS of elderly patients diagnosed with early‐stage HR+ BC. These results were similar to those of other observational studies.[10](#cam41904-bib-0010){ref-type="ref"}, [11](#cam41904-bib-0011){ref-type="ref"}

A number of factors were negatively associated with OS. Patients aged 80+ at the time of diagnosis had a higher hazard of dying immediately after diagnosis compared with patients diagnosed between the ages of 65 and 69. Older patients were more likely to have more comorbidities compared with relatively younger patients. This is most likely the primary reason why older women exhibited a higher mortality rate than younger women. Our results suggest that patients who have multiple comorbidities have a higher risk of death compared with patients who did not have comorbidities. Like previous studies, we found that the presence of several comorbidities negatively influenced the selection of treatment and OS estimates.[21](#cam41904-bib-0021){ref-type="ref"}, [22](#cam41904-bib-0022){ref-type="ref"}

The primary advantage of this study relates to the strength of its design. Selection bias was minimized by creating comparable treatment and control groups using PS matching. Additionally, we controlled for individual, facility, and area‐level factors, which contributed toward reducing biases due to unmeasured confounders. Doing so improved the internal validity of this study while maintaining its generalizability.

This study has several limitations. First, we could only adjust for observed covariates.[23](#cam41904-bib-0023){ref-type="ref"} More sophisticated approaches such as an instrumental variable approach could have been used to control for both observed and unobserved confounders. That being said, we were unable to identify a robust instrumental variable from our dataset. Additionally, physician preferences play an important role in treatment decision and outcomes. However, because our dataset did not include physician information, we could not control for physician preferences. We did not assess BC‐specific survival in this analysis despite it potentially having clinical implications. To our defense, the 5‐year survival rate for women diagnosed with early‐stage BC is approximately 100%, and our data follow the same trend (only 47 out of 5588 elderly women died from BC before PS matching). Patients diagnosed with HR+ and HER2+ patients have a high risk of death compared with patients diagnosed with HR+ with HER2‐ BC. Because SEER registers started collecting HER2 status in 2010, the majority of our data were characterized by an unknown HER2 status. Therefore, we did not assess the effect of HER2 status on the OS of elderly women; we also did not account for HER2 status in the PS matching.

Overall, radiotherapy plus HT was observed to significantly improve the OS of elderly women diagnosed with HR+ BC after PS matching. The results of this study may help inform clinical decision‐making and may serve as a stepping stone for the enactment of cost‐effectiveness analyses to inform resource allocation decision‐making.
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